ASCO 2024: Hematologic Malignancies

CME

Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2024 ASCO Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 16, 2024

Expiration: February 15, 2025

Shaji K. Kumar
Shaji K. Kumar, MD
Jeffrey P. Sharman
Jeffrey P. Sharman, MD
Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1 2
Course Completed

Introduction

In this module, recognized experts in the field discuss key studies in hematologic malignancies presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, including Shaji K. Kumar, MD, discussing multiple myeloma (MM); Eunice S. Wang, MD, discussing leukemias and myelodysplastic syndromes (MDS); and Jeffrey P. Sharman, MD, discussing key data in the treatment of lymphomas.

Please note that the key points discussed in this module are illustrated with thumbnails from Capsule Summary slidesets from the CCO coverage of the ASCO 2024, which are available here.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with hematologic malignancies do you provide care for in a typical month?

A 76-year-old man with history of type 2 diabetes and low back pain for 10 years after a motor vehicle accident presents with increased fatigue​.


Exam shows​



  • Anemia with hemoglobin: 9.7 g/dL​

  • Serum electrophoresis: M-spike, 4.2 g/dL; IF, IgG K​

  • Bone marrow aspirate: 30% plasma cells​

  • Cytogenetics (FISH): t(14;16); TP53 mutation​

  • Low-dose whole-body CT: diffuse bone lesions, spine​

  • Creatinine: creatinine clearance, 30 mL/min; β2-microglobulin, 2.5 mg/L; albumin, 3.8 g/dL; LDH, normal​

Which of the following would you recommend for this patient based on the newest data from ASCO 2024?

The phase III DREAMM-8 trial evaluating belantamab mafodotin + pom/dex vs bortezomib + pom/dex after ≥1 line of therapy (including lenalidomide) reported which of the following with belantamab mafodotin?

At ASCO 2024, results from the phase III ASC4FIRST study of oral asciminib vs investigator-selected tyrosine kinase inhibitor (IS-TKI: imatinib, nilotinib, dasatinib, or bosutinib) for patients with newly diagnosed Ph-positive CML in chronic phase were presented. Which of the following results was demonstrated?

In the phase III ECHELON-3 trial, which of the following best describes the patient population with R/R DLBCL that experienced an OS benefit with the addition of brentuximab vedotin to lenalidomide and rituximab?

Which of the following best describes the results of pirtobrutinib therapy prior to CAR T-cell therapy on outcomes in the phase I/II study from Furqan and colleagues?